"Illumina has inflicted substantial harm on Element, resulting in lost sales, diminished market share, and reduced profits," counsel for DNA-sequencing company Element Biosciences Inc. alleged in an ...

RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and ...

U.S.-based Tempus AI (TEM) stock is up in early trading on Monday. Yesterday, the company received FDA clearance for its ...

Life sciences company Element Biosciences sued Illumina on Monday in separate cases in federal courts in California and ...

Tempus AI shares are trading higher Monday morning. The company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510 (k) clearance from the U.S. Food and ...

Let us know. Catch every headline in your inbox ...

The company says a single node is capable of processing approximately 22,000 genomes annually, triple the amount of earlier releases.

Alex Zhavoronkov, founder and CEO of Insilico Medicine, explores how A.I. is driving drug discovery breakthroughs—and ...

Global in-vitro diagnostics market valued at US$ 113.3 Bn in 2024, forecasted to grow at 6.1% CAGR and surpass US$ 216.9 Bn by 2035.

Modern agriculture faces mounting challenges from climate change, soil degradation, and rising biotic and abiotic stresses, ...

OGT will now offer Qiagen's Clinical Insight Interpret bioinformatics software along with its SureSeq next-generation sequencing panels.